OSIRIS THERAPEUTICS, INC. 4

Accession 0001179110-16-020113

CIK 0001360886operating

View on SEC.gov Company Profile

Filed

Feb 23, 7:00 PM ET

Accepted

Feb 24, 8:52 PM ET

Size

26.9 KB

Accession

0001179110-16-020113

Insider Transaction Report

Form 4

Period: 2016-02-22

OSIRIS THERAPEUTICS, INC.OSIR

Debrabandere Lode

Vice President

Transactions

Disposition to Issuer
Incentive Stock Option (right to buy)
2016-02-22$5.08/sh−6,250$31,750→ 403,750 total
Exercise: $5.08From: 2016-03-23Exp: 2022-03-23→ Common Stock (6,250 underlying)
Disposition to Issuer
Incentive Stock Option (right to buy)
2016-02-22$7.73/sh−7,500$57,975→ 396,250 total
Exercise: $7.73From: 2017-02-12Exp: 2023-02-12→ Common Stock (7,500 underlying)
Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2016-02-22$14.93/sh−34,686$517,862→ 361,564 total
Exercise: $14.93From: 2017-02-06Exp: 2024-02-06→ Common Stock (34,686 underlying)
Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2016-02-22$14.93/sh−30,803$459,889→ 330,761 total
Exercise: $14.93From: 2018-02-06Exp: 2024-02-06→ Common Stock (30,803 underlying)
Disposition to Issuer
Incentive Stock Option (right to buy)
2016-02-22$14.93/sh−2,814$42,013→ 327,947 total
Exercise: $14.93From: 2017-02-06Exp: 2024-02-06→ Common Stock (2,814 underlying)
Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2016-02-22$18.40/sh−18,750$345,000→ 265,000 total
Exercise: $18.40From: 2018-03-06Exp: 2025-03-06→ Common Stock (18,750 underlying)
Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2016-02-22$18.40/sh−13,316$245,014→ 251,684 total
Exercise: $18.40From: 2019-03-06Exp: 2025-03-25→ Common Stock (13,316 underlying)
Disposition to Issuer
Non-Qualified Stock Option
2016-02-22$18.40/sh−18,750$345,000→ 283,750 total
Exercise: $18.40From: 2017-03-06Exp: 2025-03-06→ Common Stock (18,750 underlying)
Disposition to Issuer
Non-Qualified Stock Options
2016-02-22$18.40/sh−18,750$345,000→ 302,500 total
Exercise: $18.40From: 2016-03-06Exp: 2025-03-06→ Common Stock (18,750 underlying)
Disposition to Issuer
Incentive Stock Option (right to buy)
2016-02-22$14.93/sh−6,697$99,986→ 321,250 total
Exercise: $14.93From: 2018-02-06Exp: 2024-02-06→ Common Stock (6,697 underlying)
Disposition to Issuer
Incentive Stock Option (right to buy)
2016-02-22$18.40/sh−5,434$99,986→ 246,250 total
Exercise: $18.40From: 2019-03-06Exp: 2025-03-06→ Common Stock (5,434 underlying)

Footnotes (2)

[F1]Unvested incentive stock option that were forfeited concurrent with the Reporting Person's execution of post-resignation separation agreement, consistent with the provisions of the Amended and Restated 2006 Omnibus Plan. The Reporting Person's stock options that were vested on the date that he executed the separation agreement will remain exercisable for 90 days from the resignation date. The expiration of certain options were extended to one year as detailed in the separation agreement disclosed in the related Form 8-K.
[F2]Unvested non-qualified stock option that were forfeited concurrent with the Reporting Person's execution of post-resignation separation agreement, consistent with the provisions of the Amended and Restated 2006 Omnibus Plan. The Reporting Person's stock options that were vested on the date that he executed the separation agreement will remain exercisable for 90 days from the resignation date. The expiration of certain options were extended to one year as detailed in the separation agreement disclosed in the related Form 8-K.

Documents

1 file

4
edgar.xmlPrimary
FORM 4 -

Issuer

OSIRIS THERAPEUTICS, INC.

CIK 0001360886

→

Entity typeoperating

IncorporatedMD

Related Parties

filerCIK 0001360886

Filing Metadata

Form type: 4
Filed: Feb 23, 7:00 PM ET
Accepted: Feb 24, 8:52 PM ET
Size: 26.9 KB

View on SEC.gov